Lancet Infect Dis:乌干达埃博拉病毒造成的长期后遗症

2015-05-06 范伟译 MedSci原创

背景:长期埃博拉病毒疾病健康结果有限的可用数据表明感染后其后遗症的持续时间超过1年。目前在西非疫情的严重性关于其健康的影响及未来这些患者的医疗需求更需要完整的理解。方法:疫情暴发后的29个月,我们邀请2007年乌干达本迪布焦埃博拉病毒疫情成人幸存者和他们的联系人参加了一项观察性研究。我们收集关于健康状况,功能限制和人口统计数据方面的信息。我们采用ELISA法收集临床化学、血液学和线状病毒抗体的血液

背景:长期埃博拉病毒疾病健康结果有限的可用数据表明感染后其后遗症的持续时间超过1年。目前在西非疫情的严重性关于其健康的影响及未来这些患者的医疗需求更需要完整的理解。

方法:疫情暴发后的29个月,我们邀请2007年乌干达本迪布焦埃博拉病毒疫情成人幸存者和他们的联系人参加了一项观察性研究。我们收集关于健康状况,功能限制和人口统计数据方面的信息。我们采用ELISA法收集临床化学、血液学和线状病毒抗体的血液样本。分析局限于疑似和确诊的幸存者和血清反应阴性的接触者。

结果:我们招募了2007年本迪布焦埃博拉病毒70名幸存者和223名接触者。我们分析49例疑似和确诊的幸存者和157名血清反应阴性的接触者。本迪布焦埃博拉病毒的幸存者眼部不适(眼球后疼痛[RR 4.3,CI 1.9-9.6 95%;p < 0.0001),视力模糊(1.9,1.1 - 3.2;p = 0.018)),听力损失(2.3,1.2 - 4.5;p = 0.010),吞咽困难(2.1,1.1 - 3.9;p = 0.017),失眠(1.9,1.3 - 2.8;p = 0.001),关节痛(2.0,1.1-3.6;p = 0.020)的风险显著增加,以及各种全身症状。慢性健康问题(患病比率(PR)2.1,95% CI 1.2-3.6;p = 0.008)和由于记忆丧失或混乱的局限(PR 5.8,1.5-22.4;p = 0.010)也频繁的由本迪布焦埃博拉病毒的幸存者报道出来。

结论:埃博拉病毒疾病后长期后遗症持续2年以上。对相关埃博拉病毒的健康结果的定义可以改善幸存者的护理治疗,有助于了解疾病的发病机理。

原始出处:
Clark DV1, Kibuuka H2, Millard M2, Wakabi S2, Lukwago L3, Taylor A2, Eller MA4, Eller LA4, Michael NL5, Honko AN6, Olinger GG Jr6, Schoepp RJ7, Hepburn MJ8, Hensley LE6, Robb ML4.Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study.Lancet Infect Dis. 2015 Apr 21. pii: S1473-3099(15)70152-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828093, encodeId=4b4c18280936f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 21 16:08:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650335, encodeId=e81d165033523, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 03 07:08:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011982, encodeId=1c232011982de, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jan 16 16:08:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296442, encodeId=0fff1296442a4, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418776, encodeId=1fb91418e7665, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2016-02-21 hb2008ye
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828093, encodeId=4b4c18280936f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 21 16:08:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650335, encodeId=e81d165033523, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 03 07:08:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011982, encodeId=1c232011982de, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jan 16 16:08:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296442, encodeId=0fff1296442a4, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418776, encodeId=1fb91418e7665, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828093, encodeId=4b4c18280936f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 21 16:08:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650335, encodeId=e81d165033523, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 03 07:08:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011982, encodeId=1c232011982de, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jan 16 16:08:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296442, encodeId=0fff1296442a4, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418776, encodeId=1fb91418e7665, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828093, encodeId=4b4c18280936f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 21 16:08:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650335, encodeId=e81d165033523, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 03 07:08:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011982, encodeId=1c232011982de, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jan 16 16:08:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296442, encodeId=0fff1296442a4, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418776, encodeId=1fb91418e7665, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1828093, encodeId=4b4c18280936f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 21 16:08:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650335, encodeId=e81d165033523, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 03 07:08:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011982, encodeId=1c232011982de, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jan 16 16:08:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296442, encodeId=0fff1296442a4, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418776, encodeId=1fb91418e7665, content=<a href='/topic/show?id=da8839121bb' target=_blank style='color:#2F92EE;'>#后遗症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39121, encryptionId=da8839121bb, topicName=后遗症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b3422729, createdName=huirong, createdTime=Fri May 08 12:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-05-08 huirong

相关资讯

Lancet Infect Dis:埃博拉之下,疟疾防控不容乐观!

 埃博拉病毒在西非地区的持续性传播主要在圭亚那、利比里亚和塞拉利昂三国。埃博拉病毒感染者的高死亡率和高传染性已经使得这些国家的医疗卫生系统处于极其紧张的状态。因此,很少的病人可以使用医疗卫生设施,因为这些设施被关闭了。即使在正常开放的医院、诊所中,因为畏惧埃博拉病毒,门诊病人数也降低至10%。结果是,这些埃博拉疫情地区的疟疾防控近乎停滞,这直接导致了疟疾疫情的爆发和死亡率的上升。疟疾的流

Vaccine:预防啮齿类动物的埃博拉病毒长效疫苗问世

近日,来自英国普利茅斯大学的研究人员在国际学术期刊Vaccine发文宣称他们开发出针对埃博拉病毒的长效疫苗,应用该疫苗或可降低野生非洲猿的埃博拉病毒感染,对非洲埃博拉病毒的预防治疗具有重要意义。   非洲猿是埃博拉病毒向人类传播的一个主要传染源。因此预防非洲猿发生埃博拉病毒感染能够降低埃博拉病毒在非洲人口中爆发的可能性。埃博拉病毒感染对非洲猿同样具有致死性,同时也是威胁这些野

默克&NewLink 埃博拉疫苗启动四期临床试验

世卫组织WHO 5日宣布默克 -NewLink 共同研发的埃博拉疫苗将于3月7日在几内亚开始四期临床试验。 尽管西非的埃博拉疫情有所控制,但全球健康组织的权威WHO依然相当重视埃博拉病毒相关药物的研发,继默克埃博拉疫苗之后,GSK的疫苗也即将进行四期临床试验。“一定要确保疫苗供应充足。”WHO官员说道。 据统计,自2013年12月埃博拉疫情大爆发以来,已经有23,900名确诊或疑似病例,其

Nature:siRNA干预治疗埃博拉病毒感染新进展

埃博拉病毒在西非地区的流行仍未得到有效控制,其造成的病例和死亡比之前的病毒爆发流行都要严重,是一次前所未有的大灾难。近日,著名国际学术期刊nature在线发表了美国科学家关于埃博拉病毒治疗进展的相关研究。   在此研究之前,科学家们已经研发出一些病毒接触后干预手段,对返回欧洲和美国的病人进行治疗。但这些治疗手段对于治疗埃博拉病毒新暴发亚型的体内疗效仍未可知。   在该项

Lancet:中国江苏泰州新型埃博拉疫苗安全性和免疫原性的研究

背景 到现在为止,所有测试的埃博拉病毒疫苗都是根据1976年病扎伊尔爆发的毒株,我们的目的是评估一个新的重组腺病毒5型的基于矢量的埃博拉疫苗的2014年流行的糖蛋白菌株安全性和免疫原性表达。 方法我们在中国江苏省泰州县的一个站点做的随机,双盲,安慰剂对照,第一阶段的临床试验。健康成人(年龄18-60岁)依次登记和随机分配(2:1),由计算机生成的随机化块(6的块大小),接受安慰剂,低剂量的腺病毒

一个赴非抗埃医生生前发给女儿的微信

一个家庭的群由于爸爸在非洲,妈妈在四川,女儿在上海,为了交流方便,女儿专门建了一个家庭微信群他第一次点赞“爸爸,等你平安归来,女儿带你去海钓,好不好?”刚学会用微信的爸爸在下面调皮地点了个赞我们为他点赞今年1月,爸爸在执行援外医疗任务时突发大面积心肌梗塞,经全力抢救无效,不幸逝世,年仅50岁2014年2月以来,西非地区爆发了大规模的埃博拉出血热疫情,中国政府和军队第一时间向西非各国派遣医疗专家